One In A Million: Aegerion Looks To Raise The Price Of Myalept
This article was originally published in The Pink Sheet Daily
Executive Summary
Company sees “opportunity for a one-time price increase” when it takes over the lipodystrophy drug’s launch from AstraZeneca. At a current cost of about $325,000 per year, metreleptin already is on the ultra-high spectrum on par with other rare disease drugs.